This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Timmers, H. J.L.M. Articles by Pacak, K. Search for Related Content PubMed PubMed Citation Articles by Timmers, H. J.L.M. Articles by Pacak, K. Social Bookmarking                            What's this?

Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma

Henri J.L.M. Timmers, Anna Kozupa, Clara C. Chen, Jorge A. Carrasquillo, Alexander Ling, Graeme Eisenhofer, Karen T. Adams, Daniel Solis, Jacques W.M. Lenders, Karel Pacak

From the Reproductive Biology and Medicine Branch, National Institutes of Child Health and Human Development; Nuclear Medicine Department; Department of Diagnostic Radiology; Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Department of Internal Medicine, Division of General Internal Medicine; and the Department of Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

Address reprint requests to Henri J.L.M. Timmers, MD, PhD, Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, 10 Center Dr, Bldg 10, CRC, RM 1-E 3140, MSC 1109, Bethesda MD 20892-1109; e-mail: h.timmers{at}endo.umcn.nl

Purpose Germline mutations of the gene encoding subunit B of the mitochondrial enzyme succinate dehydrogenase (SDHB) predispose to malignant paraganglioma (PGL). Timely and accurate localization of these aggressive tumors is critical for guiding optimal treatment. Our aim is to evaluate the performance of functional imaging modalities in the detection of metastatic lesions of SDHB-associated PGL.

Patients and Methods Sensitivities for the detection of metastases were compared between [¹⁸F]fluorodopamine ([¹⁸F]FDA) and [¹⁸F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET), iodine-123- (¹²³I) and iodine-131 (¹³¹I) -metaiodobenzylguanidine (MIBG), ¹¹¹In-pentetreotide, and Tc-99m-methylene diphosphonate bone scintigraphy in 30 patients with SDHB-associated PGL. Computed tomography (CT) and magnetic resonance imaging (MRI) served as standards of reference.

Results Twenty-nine of 30 patients had metastatic lesions. In two patients, obvious metastatic lesions on functional imaging were missed by CT and MRI. Sensitivity according to patient/body region was 80%/65% for ¹²³I-MIBG and 88%/70% for [¹⁸F]FDA-PET. False-negative results on ¹²³I-MIBG scintigraphy and/or [¹⁸F]FDA-PET were not predicted by genotype or biochemical phenotype. [¹⁸F]FDG-PET yielded a by patient/by body region sensitivity of 100%/97%. At least 90% of regions that were false negative on ¹²³I-MIBG scintigraphy or [¹⁸F]FDA-PET were detected by [¹⁸F]FDG-PET. In two patients, ¹¹¹In-pentetreotide scintigraphy detected liver lesions that were negative on other functional imaging modalities. Sensitivities were similar before and after chemotherapy or ¹³¹I-MIBG treatment, except for a trend toward lower post- (60%/41%) versus pretreatment (80%/65%) sensitivity of ¹²³I-MIBG scintigraphy.

Conclusion With a sensitivity approaching 100%, [¹⁸F]FDG-PET is the preferred functional imaging modality for staging and treatment monitoring of SDHB-related metastatic PGL.

Supported by the Intramural Research Program of the National Institute of Child Health and Human Development/National Institutes of Health.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B Havekes, A A van der Klaauw, M M Weiss, J C Jansen, A G L van der Mey, A H J T Vriends, B A Bonsing, J A Romijn, and E P M Corssmit Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas Endocr. Relat. Cancer, June 1, 2009; 16(2): 527 - 536. [Abstract] [Full Text] [PDF]

				D. Taieb, F. Sebag, A. Barlier, L. Tessonnier, F. F. Palazzo, I. Morange, P. Niccoli-Sire, N. Fakhry, C. De Micco, S. Cammilleri, et al. 18F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature? J. Nucl. Med., May 1, 2009; 50(5): 711 - 717. [Abstract] [Full Text] [PDF]

				S. Kauhanen, M. Seppanen, J. Ovaska, H. Minn, J. Bergman, P. Korsoff, P. Salmela, J. Saltevo, T. Sane, M. Valimaki, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors Endocr. Relat. Cancer, March 1, 2009; 16(1): 255 - 265. [Abstract] [Full Text] [PDF]

				I. Ilias, C. C. Chen, J. A. Carrasquillo, M. Whatley, A. Ling, I. Lazurova, K. T. Adams, S. Perera, and K. Pacak Comparison of 6-18F-Fluorodopamine PET with 123I-Metaiodobenzylguanidine and 111In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma J. Nucl. Med., October 1, 2008; 49(10): 1613 - 1619. [Abstract] [Full Text] [PDF]

				K. P. Koopmans, P. L. Jager, I. P. Kema, M. N. Kerstens, F. Albers, and R. P.F. Dullaart 111In-Octreotide Is Superior to 123I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck Paragangliomas J. Nucl. Med., August 1, 2008; 49(8): 1232 - 1237. [Abstract] [Full Text] [PDF]

				J. T. Adler, G. Y. Meyer-Rochow, H. Chen, D. E. Benn, B. G. Robinson, R. S. Sippel, and S. B. Sidhu Pheochromocytoma: Current Approaches and Future Directions Oncologist, July 1, 2008; 13(7): 779 - 793. [Abstract] [Full Text] [PDF]

				K. P. Koopmans, J. W. B. de Groot, J. T.M. Plukker, E. G.E. de Vries, I. P. Kema, W. J. Sluiter, P. L. Jager, and T. P. Links 18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation J. Nucl. Med., April 1, 2008; 49(4): 524 - 531. [Abstract] [Full Text] [PDF]

				A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis Pheochromocytoma: an update on genetics and management Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956. [Abstract] [Full Text] [PDF]

				H. J.L.M. Timmers, J. A. Carrasquillo, M. Whatley, G. Eisenhofer, C. C. Chen, A. Ling, W. M. Linehan, P. A. Pinto, K. T. Adams, and K. Pacak Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6-18F-Fluorodopamine PET J. Nucl. Med., December 1, 2007; 48(12): 1940 - 1944. [Abstract] [Full Text] [PDF]